Aptamer Oligonucleotides as Potential Therapeutics in Hematologic Diseases

Mini Rev Med Chem. 2019;19(10):788-795. doi: 10.2174/1389557517666171002160526.

Abstract

Aptamers are single-stranded DNA or RNA oligonucleotides generated by a novel in vitro selection technique termed Systematic evolution of ligands by exponential enrichment (SELEX). During the past two decades, various aptamer drugs have been developed and many of them have entered into clinical trials. In the present review, we focus on aptamers as potential therapeutics for hematological diseases, including anemia of chronic inflammation (ACI) and anemia of chronic disease (ACD), hemophilia, thrombotic thrombocytopenic purpura (TTP) or VWD type-2B, and sickle cell disease (SCD), in particular, those that have entered into clinical trials.

Keywords: Aptamer; VWD type-2B; anemia; hemophilia; sickle cell disease; thrombotic thrombocytopenic purpura..

Publication types

  • Review

MeSH terms

  • Aptamers, Nucleotide / chemistry
  • Aptamers, Nucleotide / therapeutic use*
  • Chronic Disease / drug therapy
  • Hematologic Diseases / drug therapy*
  • Humans
  • Ligands
  • Oligonucleotides / chemistry
  • Oligonucleotides / therapeutic use*

Substances

  • Aptamers, Nucleotide
  • Ligands
  • Oligonucleotides